Working… Menu
Trial record 1 of 1 for:    university of Minnesota and Nanjing University | liver transplant
Previous Study | Return to List | Next Study

Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance (Treg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01624077
Recruitment Status : Unknown
Verified December 2014 by Ling Lu, Nanjing Medical University.
Recruitment status was:  Active, not recruiting
First Posted : June 20, 2012
Last Update Posted : February 24, 2015
University of Minnesota
Information provided by (Responsible Party):
Ling Lu, Nanjing Medical University

Brief Summary:
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for graft specific tolerance induction).

Condition or disease Intervention/treatment Phase
Chronic Rejection of Liver Transplant Biological: Regulatory T cells Phase 1

Detailed Description:

The first trial will involve the generation of CD4+CD25+CD127- Tregs from peripheral blood of pre-transplant patients, followed by a course (up to 24 months) of tacrolimus (5-10 ng/ml) treatment (to prevent chronic rejection) and the administration of the CD4+CD25+CD127- Tregs (1 x 106 cells/kg) at several intervals (for tolerance induction). The immunesuppress drugs will be gradully withdraw within one year. The number of CD4+CD25+ Tregs needed is based on the assumption that the frequencies of alloreactive CD4+ T cells with direct and indirect allospecificity were 1/104 and 1/105, respectively.

The second trial will be carried out in 1-10 year post living donor liver transplantation patients currently under immunosuppressive drug treatment. The investigators will isolate CD4+CD25+CD127- Tregs from these patients, and expand them with mismatched living donor antigens. The patients will be subsequently treated with the expanded donor-antigen specific CD4+CD25+CD127- Tregs (1 x 106 cells/kg) at several intervals, and immunosuppressive drug treatment will be withdrawn.

In both clinical trials, the investigators will monitor the number of allospecific Tregs in patients at different time periods, and to test their suppressive functions in vitro. If there will be any signs of graft rejection, patients will be switched back to immunosuppressive drug treatment. The investigators expect that the innovative Tregs immunosuppressive regimen will lead to achieve permanent liver transplantation tolerance without the use of conventional immunosuppressive drugs: the holygrail in clinical transplantation medicine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Promote Donor-specific Clinical Liver Transplantation Tolerance in Nanjing
Study Start Date : December 2014
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Regulatory T cells
Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
Biological: Regulatory T cells
Tregs will inject after liver transplantation
Other Name: Treg

Primary Outcome Measures :
  1. Patient and graft survival [ Time Frame: one year posttransplantation ]

Secondary Outcome Measures :
  1. Patient and graft survival [ Time Frame: 3 years post transplantation ]
  2. Incidence rate of biopsy-proven acute or chronic organ rejection [ Time Frame: 3 years post transplantation ]
  3. Incidence of adverse events associated with liver transplantation and immunosuppression [ Time Frame: 3 years posttransplantation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Weight greater than 50kg
  • Will be receiving a living-related primary liver allograft
  • Negative B-cell and T-cell cytotoxic and flow cytometry crossmatch
  • Normal echocardiogram (ECG) with an ejection fraction of greater than 50%
  • Parents willing to comply with the study visits

Exclusion Criteria:

  • Current active infection
  • Pregnant or breastfeeding
  • Evidence of HIV infection or known HIV positive serology
  • Antibody positive for hepatitis C virus
  • Surface antigen positive for HBV
  • Recipient or donor is positive for tuberculosis (TB), under treatment for suspected TB, or previously exposed to TB (positive Mantoux test)
  • Current cancer or a history of cancer
  • Uncontrolled concomitant infections, severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption, active peptic ulcer, or any other unstable medical condition that could interfere with this study
  • Currently receiving an investigational drug or received an investigational drug within 30 days prior to transplant
  • Currently receiving any immunosuppressive agent
  • Anticipated contraindication to taking medications orally or via nasogastric tube by the morning of Day 2 following completion of the transplant procedure
  • Require certain medications
  • Known hypersensitivity to any of the study medications,
  • Any form of substance abuse, psychiatric disorder, or other condition that, in opinion of the investigator, may interfere with the study
  • Anticipated contraindication to study medications administration for longer than 5 days post-transplant
  • History of rejection after organ transplantation
  • Muti-organ transplantation
  • Autoimmune disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01624077

Layout table for location information
China, Jiangsu
Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Sponsors and Collaborators
Nanjing Medical University
University of Minnesota
Layout table for investigator information
Study Chair: Hong Wang, MD The First Affiliated Hospital with Nanjing Medical University
Layout table for additonal information
Responsible Party: Ling Lu, Liver transplantation Center, Nanjing Medical University Identifier: NCT01624077    
Other Study ID Numbers: NJLT001
First Posted: June 20, 2012    Key Record Dates
Last Update Posted: February 24, 2015
Last Verified: December 2014
Keywords provided by Ling Lu, Nanjing Medical University:
Regulatory T cells
Liver Transplantation
Cell tolerance